Table 2: Summary of pooled major clinical responses and adverse events during short-time treatment.

AuthorDrugTime to evaluateGroupTotalPASI 75PASI 100sPGA 0/1IGA 0/1PGA 0/1AEssAEsDiscontinuations due to AEs

Papp (AMAGINE-1)Brodalumab12210 mg22218593168NRNR13142
140 mg21913251118NRNR12663
Placebo220613NRNR11233

Lebwohl (AMAGINE-2)Brodalumab12210 mg612528272481NRNR35463
140 mg610406157354NRNR365134
Ustekinumab30021065183NRNR17742
Placebo30925212NRNR16580

Lebwohl (AMAGINE-3)Brodalumab12210 mg624531229497NRNR35394
140 mg629435170377NRNR329104
Ustekinumab31321719179NRNR16821
Placebo31519113NRNR15230

PappBrodalumab12210 mg40332532NRNR3310
140 mg39301533NRNR2700
Placebo38001NRNR2310

NakagawaBrodalumab12210 mg37352235NRNR2710
140 mg37291329NRNR2100
Placebo38302NRNR1711

RichSecukinumab12150 mg13372NRNR49NR8963
Placebo671NRNR1NR4711

Paul (JUNCTURE)Secukinumab12300 mg605216NR44NR4210
150 mg614410NR33NR3930
Placebo6120NR0NR3311

Langley (ERASURE)Secukinumab12300 mg24520070NR160NR13545
150 mg24517431NR125NR14844
Placebo248112NR6NR11644

Langley (FIXTURE)Secukinumab12300 mg32724978NR202NR18144
150 mg32721947NR167NR19172
Placebo326160NR9NR16363

Blauvelt (FEATURE)Secukinumab12300 mg594625NR41NR3031
150 mg59415NR31NR3400
Placebo5900NR0NR2811

Gordon (UNCOVER-1)Ixekizumab1280 mg Q4W432357145330NRNR2641210
80 mg Q2W433386153354NRNR257610
Placebo43117214NRNR21056

Griffiths (UNCOVER-2)Ixekizumab1280 mg Q4W347269107253NRNR20485
80 mg Q2W351315142292NRNR21654
Placebo168414NRNR8921

Griffiths (UNCOVER-3)Ixekizumab1280 mg Q4W386325135291NRNR21569
80 mg Q2W385336145310NRNR20598
Placebo19314013NRNR7052

IGARASHIUstekinumab1245 mg6438NRNRNR374200
90 mg6242NRNRNR433734
Placebo322NRNRNR32122

Leonardi (PHOENIX 1)Ustekinumab1245 mg25517132NRNR15414721
90 mg25617028NRNR15813144
Placebo25580NRNR1012326

Papp (PHOENIX 2)Ustekinumab1245 mg40927374NRNR27821781
90 mg41131175NRNR30219756
Placebo410150NRNR2020488

Tsai (PEARL)Ustekinumab1245 mg61415NRNR434000
Placebo6030NRNR54223

Zhu(LOTUS)Ustekinumab1245 mg16013238NRNR1266813
Placebo162181NRNR246212

KruegerUstekinumab1245 mg644310NRNR464921
90 mg645213NRNR534231
Placebo6410NRNR04812

Blauvelt (VOYAGE 1)Guselkumab16100 mg329300123NR280NR17084
Placebo174101NR12NR8632

Reich (VOYAGE 2)Guselkumab16100 mg496328169NR417NR23587
Placebo248202NR21NR11132

GordonGuselkumab1650 mg42348NRNR33213NA
100 mg423314NRNR361905
Placebo4220NRNR32213

OHTSUKIGuselkumab1650 mg655821NR60NR3011
100 mg635317NR56NR2910
Placebo6440NR5NR3626

PappTildrakizumab12100 mg8954NANRNR555811
200 mg8662NANRNR645421
Placebo462NANRNR13101

Reich (reSURFACE 1)Tildrakizumab12100 mg30919743NRNR17914650
200 mg30819243NRNR18213085
Placebo15592NRNR117411

Reich (reSURFACE 2)Tildrakizumab12100 mg30718838NRNR16813643
200 mg31420637NRNR18615563
Placebo15690NRNR78642

Gordon (UltIMMa-1)Risankizumab16150 mg304264109267NRNR15172
Ustekinumab100701263NRNR5082
Placebo1021008NRNR5234

Gordon (UltIMMa-2)Risankizumab16150 mg294261149246NRNR13461
Ustekinumab99692462NRNR5330
Placebo98825NRNR4511

PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported; NA: not available.